Literature DB >> 28947038

Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia.

Malena Cohen-Cymberknoh1, Nir Weigert2, Alex Gileles-Hillel3, Oded Breuer3, Natalia Simanovsky4, Mieke Boon5, Kris De Boeck5, Angelo Barbato6, Deborah Snijders6, Mirella Collura7, Ugo Pradal8, Hannah Blau9, Huda Mussaffi9, Mareike Price10, Lea Bentur11, Michal Gur11, Micha Aviram12, Elie Picard13, Michal Shteinberg14, Galit Livnat14, Joseph Rivlin14, Nurith Hiller4, David Shoseyov3, Israel Amirav15, Eitan Kerem3.   

Abstract

BACKGROUND: Airway infections in Primary Ciliary Dyskinesia (PCD) are caused by different microorganisms, including pseudomonas aeruginosa (PA). The aim of this study was to investigate the association of PA colonization and the progression of lung disease in PCD.
METHODS: Data from 11PCD centers were retrospectively collected from 2008 to 2013. Patients were considered colonized if PA grew on at least two separate sputum cultures; otherwise, they were classified as non-colonized. These two groups were compared on the lung function computed tomography (CT) Brody score and other clinical parameters.
RESULTS: Data were available from 217 patients; 60 (27.6%) of whom were assigned to the colonized group. Patients colonized with PA were older and were diagnosed at a later age. Baseline forced expiratory volume at 1 s (FEV1) was lower in the colonized group (72.4 ± 22.0 vs. 80.1 ± 18.9, % predicted, p = 0.015), but FEV1 declined throughout the study period was similar in both groups. The colonized group had significantly worse CT-Brody scores (36.07 ± 24.38 vs. 25.56 ± 24.2, p = 0.034). A subgroup analysis with more stringent definitions of colonization revealed similar results.
CONCLUSIONS: Lung PA colonization in PCD is associated with more severe disease as shown by the FEV1 and CT score. However, the magnitude of decline in pulmonary function was similar in colonized and non-colonized PCD patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Airway infection; Lung deterioration; Lung function; Primary ciliary dyskinesia; Pseudomonas colonization

Mesh:

Year:  2017        PMID: 28947038     DOI: 10.1016/j.rmed.2017.08.028

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

1.  The Role of Lung Colonization in Connective Tissue Disease-Associated Interstitial Lung Disease.

Authors:  Alberto Ricci; Alessandra Pagliuca; Morgana Vermi; Dario Pizzirusso; Marta Innammorato; Raffaele Sglavo; Francesco Scarso; Simonetta Salemi; Bruno Laganà; Roberta Di Rosa; Michela D'Ascanio
Journal:  Microorganisms       Date:  2021-04-27

Review 2.  Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?

Authors:  Christopher Vinnard; Alyssa Mezochow; Hannah Oakland; Ross Klingsberg; John Hansen-Flaschen; Keith Hamilton
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

3.  Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers.

Authors:  Suzanne Crowley; Mathias Geldermann Holgersen; Kim Gjerum Nielsen
Journal:  Chron Respir Dis       Date:  2018-07-18       Impact factor: 2.444

Review 4.  Lower airway clinical outcome measures for use in primary ciliary dyskinesia research: a scoping review.

Authors:  Florian Gahleitner; James Thompson; Claire L Jackson; Jana F Hueppe; Laura Behan; Eleonora Dehlink; Myrofora Goutaki; Florian Halbeisen; Ana Paula L Queiroz; Guillaume Thouvenin; Claudia E Kuehni; Philipp Latzin; Jane S Lucas; Bruna Rubbo
Journal:  ERJ Open Res       Date:  2021-11-29

5.  Predicting factors for chronic colonization of Pseudomonas aeruginosa in bronchiectasis.

Authors:  A Pieters; M Bakker; R A S Hoek; J Altenburg; M van Westreenen; J G J V Aerts; M M van der Eerden
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-31       Impact factor: 3.267

6.  Exacerbations and Pseudomonas aeruginosa colonization are associated with altered lung structure and function in primary ciliary dyskinesia.

Authors:  G Piatti; M M De Santi; A Farolfi; G V Zuccotti; E D'Auria; M F Patria; S Torretta; D Consonni; U Ambrosetti
Journal:  BMC Pediatr       Date:  2020-04-13       Impact factor: 2.125

7.  Targeting Pseudomonas aeruginosa in the Sputum of Primary Ciliary Dyskinesia Patients with a Combinatorial Strategy Having Antibacterial and Anti-Virulence Potential.

Authors:  Giuseppantonio Maisetta; Lucia Grassi; Semih Esin; Esingül Kaya; Andrea Morelli; Dario Puppi; Martina Piras; Federica Chiellini; Massimo Pifferi; Giovanna Batoni
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

8.  Late Diagnosis of Infants with PCD and Neonatal Respiratory Distress.

Authors:  Myrofora Goutaki; Florian S Halbeisen; Angelo Barbato; Suzanne Crowley; Amanda Harris; Robert A Hirst; Bülent Karadag; Vendula Martinu; Lucy Morgan; Christopher O'Callaghan; Ugur Ozçelik; Sergio Scigliano; Santiago Ucros; Panayiotis Yiallouros; Sven M Schulzke; Claudia E Kuehni
Journal:  J Clin Med       Date:  2020-09-04       Impact factor: 4.241

Review 9.  [Management of Primary Ciliary Dyskinesia].

Authors:  J Raidt; J Brillault; F Brinkmann; A Jung; C Koerner-Rettberg; A Koitschev; H Linz-Keul; T Nüßlein; F C Ringshausen; J Röhmel; M Rosewich; C Werner; H Omran
Journal:  Pneumologie       Date:  2020-09-25

10.  International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.

Authors:  June K Marthin; Jane S Lucas; Mieke Boon; Carmen Casaulta; Suzanne Crowley; Damien M S Destouches; Ernst Eber; Amparo Escribano; Eric Haarman; Claire Hogg; Bernard Maitre; Gemma Marsh; Vendula Martinu; Antonio Moreno-Galdó; Huda Mussaffi; Heymut Omran; Petr Pohunek; Bernhard Rindlisbacher; Phil Robinson; Deborah Snijders; Woolf T Walker; Panayiotis Yiallouros; Helle Krogh Johansen; Kim G Nielsen
Journal:  ERJ Open Res       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.